$2.34
+0.05 (+2.18%)
Open$2.27
Previous Close$2.29
Day High$2.40
Day Low$2.25
52W High$3.90
52W Low$0.41
Volume—
Avg Volume575.5K
Market Cap142.65M
P/E Ratio—
EPS$-0.61
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+494.4% upside
Current
$2.34
$2.34
Target
$13.91
$13.91
$12.64
$13.91 avg
$18.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.04M | 7.06M | 6.30M |
| Net Income | 1.07M | 1.40M | 1.10M |
| Profit Margin | 15.2% | 19.8% | 17.5% |
| EBITDA | 1.93M | 2.06M | 1.69M |
| Free Cash Flow | 1.16M | 752.4K | 1.14M |
| Rev Growth | -2.7% | +19.8% | -1.2% |
| Debt/Equity | 1.45 | 1.09 | 1.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |